<DOC>
	<DOC>NCT01096030</DOC>
	<brief_summary>This will be an uncontrolled, open-label, non-randomized, phase I study. The primary objectives of this study are to define the pharmacokinetics (PK) and to evaluate the safety and tolerability of Regorafenib administered orally as a single agent in Chinese patients with advanced solid tumors. The secondary objectives are to evaluate tumor response of patients treated with Regorafenib.</brief_summary>
	<brief_title>Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Male or female Chinese subjects &gt;/ 18 years Advanced, histologically or cytologically confirmed solid tumors Subjects malignancies must be refractory to standard treatment or have no standard therapy available, or the subject actively refused any treatment that would be regarded standard, and/or if, in the judgment of the investigator or his/her designated associate(s), experimental treatment is clinically and ethically acceptable. Eastern Cooperative Oncology Group performance status (ECOGPS) 01; Adequate bone marrow, liver and renal function Life expectancy of at least 3 months Unstable/uncontrolled cardiac disease History of arterial or venous thrombotic or embolic events Malabsorption condition Severe renal impairment; persistent proteinuria &gt;/= Grade 3 Symptomatic metastatic brain or meningeal tumors Clinically significant bleeding &gt;/=Grade 3 within 30 days before start of study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Advanced</keyword>
	<keyword>Refractory solid tumors</keyword>
</DOC>